Potassium chloride

Generic Name: Potassium chloride

Brand Names: Bi-peglyte, Bss, Bss Ophthalmic Solution, Cardioplegic, Citrasate, Colyte, Dextrose and Electrolyte No. 75, Diphen, Eye Stream, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Glycerolyte 57, Golytely, H.E.L.P.bicel, Hemosate Ultra, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S pH 7.4, Isoplate, K 45, K-tab, Klor-con, Lactated Ringers, Moviprep, Naturalyte, Normosol-R, Nulytely, Nxstage Pureflow, Olimel, Peglyte, Periolimel, Phoxillum, Physiolyte, Physiosol, Plasma-lyte, Plasma-lyte 148, Plasma-lyte 148 In 5 % Dextrose, Plasma-lyte R, Plasmalyte A, Plegisol, Plenvu, Pokonza, Prismasol, Procalamine 3, Ringers, Selectbag One, Suflave, Tis-U-sol

Drug Type: Small Molecule

Chemical Formula: ClK

CAS Number: 7447-40-7

Unique Ingredient Identifier: 660YQ98I10

Background: A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion.

Indication: For use as an electrolyte replenisher and in the treatment of hypokalemia.

Associated Conditions: Dehydration, Dry Mouth, Hypokalemia, Hypotonic Dehydration, Hypovolaemia, Isotonic Dehydration, Markedly Reduced Food Intake, Metabolic Acidosis, Hypodermoclysis, Mild Metabolic acidosis, Mild, moderate Metabolic Acidosis, Ocular edema

Associated Therapies: Acid- Base Balance, Bowel preparation therapy, Electrolyte replacement, Fluid replacement therapy, Haemofiltration, Hemodialysis Treatment, Parenteral Nutrition, Parenteral rehydration therapy, Plasma Volume Replacement, Urine alkalinization therapy, Fluid and electrolyte maintenance therapy

Clinical Trials

A Comparison of 5 Low Volume Bowel Preparations

Phase 4

Completed

Conditions: Bowel Preparation for Colonoscopy

Interventions: Drug: SUPREP
Drug: MiraLAX
Drug: MoviPrep
Other: Gatorade

First Posted Date: 2012-11-01

Last Posted Date: 2017-03-24

Lead Sponsor: Gastroenterology Services, Ltd.

Target Recruit Count: 1079

Registration Number: NCT01719653

Locations: 🇺🇸
Gastroenterology Services, Downers Grove, Illinois, United States

Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy

Phase 2

Completed

Conditions: Colon Cancer

Interventions: Drug: NER1006
Drug: MOVIPREP

First Posted Date: 2012-10-26

Last Posted Date: 2014-11-20

Lead Sponsor: Norgine

Target Recruit Count: 240

Registration Number: NCT01714466

Locations: 🇩🇪
PAREXEL International Early Product Development Unit, Berlin, Germany
🇩🇪
Parexel International GmbH, Berlin, Germany

A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: MOVIPREP
Drug: CitraFleet

First Posted Date: 2012-09-21

Last Posted Date: 2015-03-31

Lead Sponsor: Norgine

Target Recruit Count: 398

Registration Number: NCT01689792

Locations: 🇩🇪
Klinikum Aschaffenburg, Aschaffenburg, Germany

A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction

Phase 4

Completed

Conditions: Temporomandibular Joint Dysfunction
Arthrocentesis
Pain

Interventions: Drug: Corticosteroid
Drug: Lactated Ringers
Drug: Hyaluronic acid

First Posted Date: 2012-02-02

Last Posted Date: 2017-05-05

Lead Sponsor: Emory University

Target Recruit Count: 102

Registration Number: NCT01524913

Locations: 🇺🇸
University of Cinncinati, Cinncinati, Ohio, United States
🇺🇸
University California Los Angeles, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 2 locations

Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients

Phase 4

Completed

Conditions: Thoracic Surgery
Cardiac Surgery
Critically Ill

Interventions: Drug: Potassium Chloride

First Posted Date: 2010-03-11

Last Posted Date: 2013-01-21

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 1225

Registration Number: NCT01085071

Locations: 🇳🇱
University Medical Center Groningen, University of Groningen, Groningen, Netherlands

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

Phase 1

Withdrawn

Conditions: Pre-hypertension
Hypertension

Interventions: Drug: Potassium, Magnesium, Citrate
Drug: Potassium Chloride

First Posted Date: 2010-02-24

Last Posted Date: 2019-02-11

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT01074918

Locations: 🇺🇸
Dallas VA Medical Center, Dallas, Texas, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation

Phase 4

Completed

Conditions: Preparation for Colonoscopy

Interventions: Drug: Gatorade/Miralax
Drug: NuLytely
Drug: Placebo
Drug: Bisacodyl

First Posted Date: 2010-02-05

Last Posted Date: 2013-11-18

Lead Sponsor: Gastroenterology Services, Ltd.

Target Recruit Count: 600

Registration Number: NCT01063049

Locations: 🇺🇸
Gastroenterology Services, Downers Grove, Illinois, United States

Metabolic Acidosis in Renal Transplant Patients

Phase 2

Completed

Conditions: Renal Transplant Patients
Metabolic Acidosis
Physical Capacity
Bone Disease
Mineral Metabolism

Interventions: Drug: Potassium citrate
Drug: Potassium chloride

First Posted Date: 2009-06-04

Last Posted Date: 2010-10-22

Lead Sponsor: University of Zurich

Target Recruit Count: 30

Registration Number: NCT00913796

Locations: 🇨🇭
University Hospital of Zurich, Zurich, Switzerland

Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI

Phase 1

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Stem cell
Drug: Plasmalyte A

First Posted Date: 2009-04-20

Last Posted Date: 2013-03-05

Lead Sponsor: Stempeutics Research Pvt Ltd

Target Recruit Count: 20

Registration Number: NCT00883727

Locations: 🇮🇳
Care Hospital, Hyderabad, Andhra Pradesh, India
🇮🇳
MS Ramaiah Memorial Hospital, Bangalore, Karnataka, India
🇮🇳
Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India

and more 1 locations

Mesenchymal Stem Cells in Critical Limb Ischemia

Phase 1

Completed

Conditions: Critical Limb Ischemia

Interventions: Drug: Plasmalyte A
Drug: mesenchymal stem cells

First Posted Date: 2009-04-20

Last Posted Date: 2013-03-05

Lead Sponsor: Stempeutics Research Pvt Ltd

Target Recruit Count: 20

Registration Number: NCT00883870

Locations: 🇮🇳
Amrita Institute of Medical Sciences, Kochi, Kerala, India
🇮🇳
M.S.Ramaiah Memorial Hospital, Bangalore, Karnataka, India
🇮🇳
Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy